liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Garvin, Stina
Publications (10 of 17) Show all publications
Garvin, S., Oda, H., Arnesson, L.-G., Lindström, A. & Shabo, I. (2018). Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery. Journal of Cancer Research and Clinical Oncology, 144(7), 1253-1263
Open this publication in new window or tab >>Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery
Show others...
2018 (English)In: Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, E-ISSN 1432-1335, Vol. 144, no 7, p. 1253-1263Article in journal (Refereed) Published
Abstract [en]

Cancer cell fusion with macrophages results in highly tumorigenic hybrids that acquire genetic and phenotypic characteristics from both maternal cells. Macrophage traits, exemplified by CD163 expression, in tumor cells are associated with advanced stages and poor prognosis in breast cancer (BC). In vitro data suggest that cancer cells expressing CD163 acquire radioresistance. Tissue microarray was constructed from primary BC obtained from 83 patients treated with breast-conserving surgery, 50% having received postoperative radiotherapy (RT) and none of the patients had lymph node or distant metastasis. Immunostaining of CD163 in cancer cells and macrophage infiltration (MI) in tumor stroma were evaluated. Macrophage:MCF-7 hybrids were generated by spontaneous in vitro cell fusion. After irradiation (0, 2.5 and 5 Gy gamma-radiation), both hybrids and their maternal MCF-7 cells were examined by clonogenic survival. CD163-expression by cancer cells was significantly associated with MI and clinicopathological data. Patients with CD163-positive tumors had significantly shorter disease-free survival (DFS) after RT. In vitro generated macrophage:MCF-7 hybrids developed radioresistance and exhibited better survival and colony forming ability after radiation compared to maternal MCF-7 cancer cells. Our results suggest that macrophage phenotype in tumor cells results in radioresistance in breast cancer and shorter DFS after radiotherapy.

Place, publisher, year, edition, pages
SPRINGER, 2018
Keywords
Tumor-associated macrophages; CD163; Breast cancer; Radiotherapy; Treatment resistance
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-149466 (URN)10.1007/s00432-018-2646-0 (DOI)000435380600005 ()29725763 (PubMedID)
Note

Funding Agencies|Swedish Society of Medicine [SLS-178731]; County Council of Ostergotland, Sweden [LIO-204441]

Available from: 2018-07-05 Created: 2018-07-05 Last updated: 2019-04-10
Jedlinski, A., Garvin, S., Johansson, A.-C., Edqvist, P.-H., Pontén, F. & Roberg, K. (2017). Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction of EGFR, pEGFR, and pSrc. Journal of Oral Pathology & Medicine (9), 717-724
Open this publication in new window or tab >>Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction of EGFR, pEGFR, and pSrc
Show others...
2017 (English)In: Journal of Oral Pathology & Medicine, ISSN 0904-2512, E-ISSN 1600-0714, no 9, p. 717-724Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The aim of this study was to validate in vitro drug sensitivity testing of head and neck squamous cell carcinoma (HNSCC)cell lines in an in vivo xenograft model, and to identify treatment-induced changes in the EGFR signaling pathway that could be used as markersfor cetuximab treatment response.

METHODS: The in vitro cetuximab sensitivity of two HNSCC cell lines, UT-SCC-14 and UTSCC-45, was assessed using a crystal violet assay. In order to determine the corresponding in vivo sensitivity, UT-SCC-14 and UT-SCC-45 xenografts were generated in female BALB/c (nu/nu) nude mice. Mice were given three injections of intraperitoneal cetuximab or PBS and the tumor volume was recorded continuously. The expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR (pEGFR), phosphorylated Src (pSrc), and Ki67 was investigated by immunohistochemistry.

RESULTS: The treatment sensitive UT-SCC-14 cells were found to have an intrinsic cetuximab sensitivity (ICmabS) of 0.15 whereas the ICmabS of the insensitive cell line UT-SCC-45 was 0.78. The corresponding size ratio between untreated and cetuximab treated xenografts was 0.22 and 0.83 for UT-SCC-14 and UT-SCC-45, respectively. UT-SCC-14 cells had a higher baseline expression of pEGFR as compared to UT-SCC-45. Furthermore, in UT-SCC-14 xenografts there was a decrease in EGFR, pEGFR and pSrc upon cetuximab treatment. In contrast, a slight cetuximab-induced increase in EGFR, pEGFR and pSrc was observed in treatment-resistant UT-SCC-45 xenografts.

CONCLUSIONS: The in vitro treatment sensitivity was reproduced in the in vivo model and cetuximab sensitivity was found to associate with a treatment-induced reduction in pEGFR and pSrc.

Place, publisher, year, edition, pages
John Wiley & Sons, 2017
National Category
Medical and Health Sciences Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-113742 (URN)10.1111/jop.12545 (DOI)000412303500009 ()28036101 (PubMedID)
Note

Funding agencies: Foundation of Ake Wiberg; County Council of Ostergotland; Research Funds of Linkoping University Hospital; Cancer Foundation of Ostergotland; Foundation of Magn. Bergvall; The Swedish Cancer Society [2010/545]

The previous status of this publication was Manuscript

Available from: 2015-01-29 Created: 2015-01-29 Last updated: 2018-05-03Bibliographically approved
Lindström, A., Midtbö, K. M., Arnesson, L.-G., Garvin, S. & Shabo, I. (2017). Fusion between M2-macrophages and cancer cells results in a subpopulation of radioresistant cells with enhanced DNA-repair capacity. OncoTarget, 8(31), 51370-51386
Open this publication in new window or tab >>Fusion between M2-macrophages and cancer cells results in a subpopulation of radioresistant cells with enhanced DNA-repair capacity
Show others...
2017 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 8, no 31, p. 51370-51386Article in journal (Refereed) Published
Abstract [en]

Cell fusion is a natural biological process in normal development and tissue regeneration. Fusion between cancer cells and macrophages results in hybrids that acquire genetic and phenotypic characteristics from both maternal cells. There is a growing body of in vitro and in vivo data indicating that this process also occurs in solid tumors and may play a significant role in tumor progression. However, investigations of the response of macrophage: cancer cell hybrids to radiotherapy have been lacking. In this study, macrophage: MCF-7 hybrids were generated by spontaneous in vitro cell fusion. After irradiation, both hybrids and their maternal MCF-7 cells were treated with 0 Gy, 2.5 Gy and 5 Gy.-radiation and examined by clonogenic survival and comet assays at three time points (0 h, 24 h, and 48 h). Compared to maternal MCF-7 cells, the hybrids showed increased survival fraction and plating efficiency (colony formation ability) after radiation. The hybrids developed less DNA-damage, expressed significantly lower residual DNA-damage, and after higher radiation dose showed less heterogeneity in DNA-damage compared to their maternal MCF-7 cells. To our knowledge this is the first study that demonstrates that macrophage: cancer cell fusion generates a subpopulation of radioresistant cells with enhanced DNA-repair capacity. These findings provide new insight into how the cell fusion process may contribute to clonal expansion and tumor heterogeneity. Furthermore, our results provide support for cell fusion as a mechanism behind the development of radioresistance and tumor recurrence.

Place, publisher, year, edition, pages
IMPACT JOURNALS LLC, 2017
Keywords
cell fusion; M2-macrophage; radiotherapy; breast cancer; radioresistance
National Category
Cell and Molecular Biology
Identifiers
urn:nbn:se:liu:diva-140058 (URN)10.18632/oncotarget.17986 (DOI)000406717200095 ()
Note

Funding Agencies|National Organization of Breast Cancer Associations (Sweden); Swedish Cancer Society (Sweden); County Council of Ostergotland (Sweden)

Available from: 2017-08-28 Created: 2017-08-28 Last updated: 2018-05-03
Tiefenböck Hansson, K., Haapaniemi, A., Farnebo, L., Palmgren, B., Tarkkanen, J., Farnebo, M., . . . Roberg, K. (2017). WRAP53 beta, survivin and p16(INK4a) expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0-T3N0 glottic laryngeal cancer. Oncology Reports, 38(4), 2062-2068
Open this publication in new window or tab >>WRAP53 beta, survivin and p16(INK4a) expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0-T3N0 glottic laryngeal cancer
Show others...
2017 (English)In: Oncology Reports, ISSN 1021-335X, E-ISSN 1791-2431, Vol. 38, no 4, p. 2062-2068Article in journal (Refereed) Published
Abstract [en]

The current treatment recommendation for T2-3N0M0 glottic squamous cell carcinoma (SCC) in the Nordic countries comprises of radiotherapy (RT) and chemoradiotherapy (CRT). Tumor radiosensitivity varies and another option is primary surgical treatment, which underlines the need for predictive markers in this patient population. The aim of the present study was to investigate the relation of the proteins WRAP53 beta, survivin and p16INK4a to RT/CRT response and ultimate outcome of patients with T2-T3N0 glottic SCC. Protein expression was determined using immunohistochemistry on tumors from 149 patients consecutively treated with RT or CRT at Helsinki University Hospital, Karolinska University Hospital, and Linkping University Hospital during 1999-2010. Our results demonstrate a significantly better 5-year relapse-free survival, disease-free survival (DFS), disease-specific survival and overall survival of patients with T3N0 tumors treated with CRT compared with RT alone. Patients with tumors showing a cytoplasmic staining of WRAP53 beta revealed significantly worse DFS compared with those with nuclear staining. For survivin, we observed a trend towards better 5-year DFS in patients with strong nuclear survivin expression compared with those with weak nuclear survivin expression (p=0.091). Eleven (7%) tumors showed p16 positivity, with predilection to younger patients, and this age group of patients with p16-positive SCC had a significantly better DFS compared with patients with p16-negative SCC. Taken together, our results highlight WRAP53 beta as a potential biomarker for predicting RT/CRT response in T2-T3N0 glottic SCC. p16 may identify a small but distinct group of glottic SCC with favorable outcome. Furthermore, for T3N0 patients better outcome was observed following CRT compared to RT alone.

Place, publisher, year, edition, pages
SPANDIDOS PUBL LTD, 2017
Keywords
head and neck cancer; radiotherapy; chemoradiotherapy; survival; recurrence; biomarker; WRAP53 beta; survivin; p16
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-141926 (URN)10.3892/or.2017.5898 (DOI)000411688200017 ()28849066 (PubMedID)
Note

Funding Agencies|Swedish Cancer Society [2010/545]; County Council of Ostergotland; Research Funds of Linkoping University Hospital; Finnish Cancer Society; Finnish Medical Foundation; Finnish-Norwegian Medical Foundation; Helsinki University Hospital Research Funds [TYH2015204]

Available from: 2017-10-13 Created: 2017-10-13 Last updated: 2018-05-03
Farnebo, L., Stjernstrom, A., Fredrikson, M., Ansell, A., Garvin, S. & Thunell, L. (2015). DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. DNA Repair, 31, 64-72
Open this publication in new window or tab >>DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck
Show others...
2015 (English)In: DNA Repair, ISSN 1568-7864, E-ISSN 1568-7856, Vol. 31, p. 64-72Article in journal (Refereed) Published
Abstract [en]

Head and neck squamous cell carcinomas (HNSCC) are a heterogenous group of tumors with a high rate of early recurrences, second primary tumors, and mortality. Despite advances in diagnosis and treatment over the past decades, the overall 5-year survival rate remains around 50%. Since the head-and neck-region is continuously exposed to potentially DNA-damaging exogenous and endogenous factors, it is reasonable to expect that the DNA repair genes play a part in the development, progression, and outcome of HNSCC. The aim of this study was to investigate the SNPs XPC A499V, XPD K751Q XRCC1 R399Q and XRCC3 T241M as potential risk factors and indicators of survival among Caucasian patients. One-hundred-sixty-nine patients as well as 344 healthy controls were included and genotyped with PCR-RFLP. We showed that XPC A499V was associated with increased risk of HNSCC, especially laryngeal carcinoma. Among women, XPD K751Q was associated with increased risk of oral SCC. Furthermore, XPD homozygous mutant individuals had the shortest survival time, a survival time that increased however after full dose radiotherapy. Wild-type individuals of XRCC3 T241M demonstrated an earlier age of onset. HPV-positive never smokers had lower frequencies of p53 mutation. Among HNSCC patients, HPV-positivity was significantly associated with XRCC1 R399Q homozygous mutant genotype. Moreover, combinations of putative risk alleles seemed to act synergistically, increasing the risk of HNSCC. In conclusion, our results suggest that SNPs of the DNA repair genes XPC, XPD, XRCC1, and XRCC3 may affect risk and survival of HNSCC. (C) 2015 Elsevier B.V. All rights reserved.

Place, publisher, year, edition, pages
Elsevier, 2015
Keywords
Head and neck squamous cell carcinoma; XPC; XPD; HPV; p53; Overall survival
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-120212 (URN)10.1016/j.dnarep.2015.05.003 (DOI)000357138600007 ()26001739 (PubMedID)
Note

Funding Agencies|Swedish Cancer Society; Laryngfonden

Available from: 2015-07-21 Created: 2015-07-20 Last updated: 2017-12-04
Garvin, S., Tiefenböck, K., Farnebo, L., Thunell, L., Farnebo, M. & Roberg, K. (2015). Nuclear expression of WRAP53 beta is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma. Oral Oncology, 51(1), 24-30
Open this publication in new window or tab >>Nuclear expression of WRAP53 beta is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma
Show others...
2015 (English)In: Oral Oncology, ISSN 1368-8375, E-ISSN 1879-0593, Vol. 51, no 1, p. 24-30Article in journal (Refereed) Published
Abstract [en]

Objectives: Today there are no reliable predictive markers for radiotherapy response in head and neck squamous cell carcinoma (HNSCC), leading to both under-and over-treatment of patients, personal suffering, and negative socioeconomic effects. Inherited mutation in WRAP53 beta (WD40 encoding RNA Antisense to p53), a protein involved in intracellular trafficking, dramatically increases the risk of developing HNSCC. The purpose of this study was to investigate whether WRAP53 beta can predict response to radiotherapy in patients with HNSCC. Materials and methods: Tumor biopsies from patients with HNSCC classified as responders or non-responders to radiotherapy were examined for the expression of the WRAP53 beta protein and single nucleotide polymorphisms in the corresponding gene employing immunohistochemistry and allelic discrimination, respectively. In addition, the effect of RNAi-mediated downregulation of WRAP53 beta on the intrinsic radiosensitivity of two HNSCC cell lines was assed using crystal violet and clonogenic assays. Results: Nuclear expression of WRAP53 beta was significantly associated with better response to radiotherapy and improved patient survival. Downregulation of WRAP53 beta with siRNA in vitro enhanced cellular resistance to radiation. Conclusions: Our findings suggest that nuclear expression of WRAP53 beta promotes tumor cell death in response to radiotherapy and is a promising predictor of radiotherapy response in patients with HNSCC.

Place, publisher, year, edition, pages
Elsevier, 2015
Keywords
Head and neck cancer; Radiotherapy; Predictive factors; Survivin; WRAP53
National Category
Cancer and Oncology Otorhinolaryngology
Identifiers
urn:nbn:se:liu:diva-113161 (URN)10.1016/j.oraloncology.2014.10.003 (DOI)000346210900007 ()25456005 (PubMedID)
Note

Funding Agencies|Swedish Laryng Foundation; Ake Wiberg Foundation; Swedish Cancer Society [2008/552, 2010/545]; County Council of Ostergotland; Research Funds of Linkoping University Hospital

Available from: 2015-01-14 Created: 2015-01-12 Last updated: 2017-12-05
Welander, J., Garvin, S., Bohnmark, R., Isaksson, L., Wiseman, R. W., Söderkvist, P. & Gimm, O. (2013). Editorial Material: Germline SDHA Mutation Detected by Next-Generation Sequencing in a Young Index Patient With Large Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 98(8), E1379-E1380
Open this publication in new window or tab >>Editorial Material: Germline SDHA Mutation Detected by Next-Generation Sequencing in a Young Index Patient With Large Paraganglioma
Show others...
2013 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 98, no 8, p. E1379-E1380Article in journal, Editorial material (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Endocrine Society, 2013
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-97245 (URN)10.1210/jc.2013-1963 (DOI)000322781300012 ()
Available from: 2013-09-05 Created: 2013-09-05 Last updated: 2018-04-25
Farnebo, L., Tiefenböck, K., Ansell, A., Thunell, L., Garvin, S. & Roberg, K. (2013). Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. International Journal of Cancer, 133(8), 1994-2003
Open this publication in new window or tab >>Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients
Show others...
2013 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 133, no 8, p. 1994-2003Article in journal (Refereed) Published
Abstract [en]

Head and neck squamous cell carcinoma (HNSCC) is a malignancy that is associated with severe mortality despite advances in therapy. Todays standard treatment most commonly includes radiotherapy, often combined with chemotherapy or surgery. There are so far no established biomarkers to predict response to radiation, and thus the aim of this study was to investigate a series of markers that could potentially identify HNSCC patients who would benefit from radiotherapy. The selected markers, both proteins (epidermal growth factor receptor, survivin and p53), and single nucleotide polymorphisms (SNPs) in the genes of XRCC3, XRCC1, XPC, XPD, MDM2, p53 and FGFR4 were correlated to the response to radiotherapy and overall survival. Investigations were performed on pretreatment tumor biopsies from patients classified as responders or nonresponders to radiotherapy. Protein expression was examined using immunohistochemistry and the genotyping of specific SNPs was analyzed using PCR-RFLP or pyrosequencing. We found that survivin expression was significantly stronger in the responder group (p = 0.003) and that patients with a strong survivin expression had a significantly better overall survival (p andlt; 0.001). Moreover, downregulation of survivin by siRNA in two HNSCC cell lines significantly decreased their sensitivity to radiation. Among the SNPs analyzed, patients with the XPD Lys751Gln SNP had a significantly shorter overall survival (p = 0.048), and patients with the FGFR4 Gly388Arg SNP had a significantly longer overall survival (p = 0.010). In conclusion, our results suggest that survivin plays an important role in the response to radiotherapy and may be a useful marker for predicting radiotherapy response in patients with HNSCC. less thanbrgreater than less thanbrgreater thanWhats new? Resistance to radiation therapy is a significant problem in the treatment of head and neck squamous cell carcinoma (HNSCC) and has created a need for the discovery of markers predictive of radiotherapy response. One promising marker is survivin, an inhibitor of apoptosis. Here, in pre-treatment biopsies from 40 patients with HNSCC, strong survivin expression was significantly associated with response to radiotherapy and increased overall survival. The data also indicate that single nucleotide polymorphisms in the genes XPD and FGFR4 are other possible predictors of overall survival after radiotherapy.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2013
Keywords
head and neck tumors, radiotherapy, survivin, single nucleotide polymorphism
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-97229 (URN)10.1002/ijc.28200 (DOI)000322908600025 ()
Note

Funding Agencies|Swedish Cancer Society|2008/5522010/545|Swedish Laryng Foundation||Foundation of Ake Wiberg||County Council of Ostergotland||Research Funds of Linkoping University Hospital||

Available from: 2013-09-06 Created: 2013-09-05 Last updated: 2017-12-06
Jerhammar, F., Ceder, R., Garvin, S., Grenman, R., C Grafstrom, R. & Roberg, K. (2010). Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. CANCER BIOLOGY and THERAPY, 10(12), 1244-1251
Open this publication in new window or tab >>Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma
Show others...
2010 (English)In: CANCER BIOLOGY and THERAPY, ISSN 1538-4047, Vol. 10, no 12, p. 1244-1251Article in journal (Refereed) Published
Abstract [en]

Radiotherapy remains the backbone of head and neck cancer therapy but response is sometimes impeded by tumor radioresistance. Identifying predictive biomarkers of radiotherapy response is a crucial step towards personalized therapy. The aim of this study was to explore gene expression data in search of biomarkers predictive of the response to radiotherapy in head and neck squamous cell carcinoma (HNSCC). Microarray analysis was performed on five cell lines with various intrinsic radiosensitivity, selected from a panel of 29 HNSCC cell lines. The bioinformatics approach included Gene Ontology (GO) enrichment profiling and Ingenuity Pathway Analysis (IPA). The GO-analysis detected 16 deregulated categories from which development, receptor activity and extracellular region represented the largest groups. Fourteen hub genes (CEBPA, CEBPB, CTNNB1, FN1, MYC, MYCN, PLAU, SDC4, SERPINE1, SP1, TAF4B, THBS1, TP53 and VLDLR) were identified from the IPA network analysis. The hub genes in the highest ranked network, (FN1, SERPINE1, THBS1 and VLDLR) were further subjected to qPCR analysis in the complete panel of 29 cell lines. Of these genes, high FN1 expression associated to high intrinsic radiosensitivity (p = 0.047). In conclusion, gene ontologies and hub genes of importance for intrinsic radiosensitivity were defined. The overall results suggest that FN1 should be explored as a potential novel biomarker for radioresistance.

Place, publisher, year, edition, pages
Landes Bioscience, 2010
Keywords
head and neck cancer, predictive markers, radiotherapy, microarray, gene ontology, pathway analysis, fibronectin 1
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-64243 (URN)10.4161/cbt.10.12.13432 (DOI)000285388400007 ()
Available from: 2011-01-17 Created: 2011-01-17 Last updated: 2012-03-29Bibliographically approved
Törnroos, A., Garvin, S. & Olsson, H. (2009). The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer. ACTA ONCOLOGICA, 48(8), 1152-1156
Open this publication in new window or tab >>The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer
2009 (English)In: ACTA ONCOLOGICA, ISSN 0284-186X, Vol. 48, no 8, p. 1152-1156Article in journal (Refereed) Published
Abstract [en]

Background. The positive correlation between the number of recovered benign lymph nodes and patient prognosis is well established for stage II colon cancer patients. One theory explaining this correlation focuses on potential understaging of cancer specimen, implying that a specimen with few examined lymph nodes is likely to be assigned a lower N-stage than the correct one. Understaging may be the result of an insufficient examination of the specimen post-operatively, whereby few lymph nodes are recovered and potential lymph node metastases are overlooked. This study aims to investigate the association between the total lymph node harvest and the number of lymph node metastases in colon cancer specimen. Material and methods. We studied the original pathology reports of 649 patients diagnosed with T3 adenocarcinoma of the colon at the Department of Clinical Pathology and Genetics at Linkoping University Hospital, Linkoping, Sweden between the years 2000 and 2008. Patient demographics, specimen staging data, and lymph node recovery data were collected for each case. Results. We found a positive association between the total lymph node harvest and the number of lymph node metastases per specimen. For every additional recovered lymph node 0.17 (95% CI: 0.15-0.19) metastases were detected (pandlt;0.001). Discussion. Our results support the conclusion that there is no minimum number of recovered lymph nodes at which an accurate determination of nodal status can be assured. Rather than focusing on a recommended minimum number of nodes, efforts should be shifted towards developing methods assuring that colon cancer specimen are dissected in a standardized way that optimizes the lymph node harvest.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-52413 (URN)10.3109/02841860902896097 (DOI)
Available from: 2010-01-11 Created: 2009-12-18 Last updated: 2010-11-11
Organisations

Search in DiVA

Show all publications